Media stories about Corcept Therapeutics (NASDAQ:CORT) have trended somewhat positive on Saturday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Corcept Therapeutics earned a news impact score of 0.14 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 47.1992444439103 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the news articles that may have impacted Accern Sentiment’s analysis:

Several research analysts recently weighed in on the stock. Piper Jaffray Companies set a $30.00 price target on shares of Corcept Therapeutics and gave the stock a “buy” rating in a research report on Tuesday. Zacks Investment Research downgraded shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Stifel Nicolaus assumed coverage on shares of Corcept Therapeutics in a research report on Thursday, August 31st. They set a “buy” rating and a $20.00 price target for the company. BidaskClub upgraded shares of Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 18th. Finally, Ladenburg Thalmann Financial Services set a $20.00 price target on shares of Corcept Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $18.20.

Shares of Corcept Therapeutics (CORT) traded down $1.78 during midday trading on Friday, reaching $17.32. 3,408,299 shares of the company traded hands, compared to its average volume of 1,654,092. The company has a market cap of $2.24 billion, a PE ratio of 67.97 and a beta of 2.04.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.13 by ($0.02). Corcept Therapeutics had a net margin of 27.28% and a return on equity of 67.59%. The business had revenue of $42.70 million during the quarter, compared to analyst estimates of $41.64 million. During the same quarter in the prior year, the firm posted $0.02 earnings per share. Corcept Therapeutics’s revenue for the quarter was up 96.8% compared to the same quarter last year. sell-side analysts expect that Corcept Therapeutics will post 0.44 EPS for the current fiscal year.

WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Corcept Therapeutics (CORT) Stock Price” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.